Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25857076 | 0.93 | ALDH1A1 (0.38) | ALDH1A1KMT2AMEN1LMNAMAPT | |
| SCHEMBL24746661 | 0.85 | ALDH1A1 (0.47) | ALDH1A1MAPTGAANPC1RAB9A | |
| SCHEMBL24746985 | 0.83 | ALDH1A1 (0.39) | ALDH1A1KMT2AMAPTGAANPC1 | |
| SCHEMBL25857073 | 0.79 | ALDH1A1 (0.42) | ALDH1A1KMT2AMEN1LMNAMAPT | |
| SCHEMBL25857060 | 0.76 | ALDH1A1 (0.45) | ALDH1A1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL25857062 | 0.76 | ALDH1A1 (0.45) | ALDH1A1KMT2AMEN1MAPTNPC1 | |
| SCHEMBL25857160 | 0.73 | ALDH1A1 (0.31) | ALDH1A1NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL25857181 | 0.72 | ALDH1A1 (0.38) | ALDH1A1KMT2AMEN1LMNAMAPT | |
| SCHEMBL24746659 | 0.71 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1LMNAGAA | |
| SCHEMBL25857050 | 0.71 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11801228-B2 | Modified guanidine-containing polymers for biologic delivery | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230225982-A1 | MODIFIED GUANIDINE-CONTAINING POLYMERS FOR BIOLOGIC DELIVERY | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230225982-A1 | MODIFIED GUANIDINE-CONTAINING POLYMERS FOR BIOLOGIC DELIVERY | GMPS, RNMT, GUCY1A1 | ALDH1A1 1829/4885KMT2A 2590/4885MEN1 2661/4885 |
| US-11801228-B2 | Modified guanidine-containing polymers for biologic delivery | GMPS, RNMT, GUCY1A1 | ALDH1A1 1829/4885KMT2A 2590/4885MEN1 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.